SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A beloved 9-year-old tabby cat, cherished mascot of Randa's Market, and the heart of the Mission District. KitKat was more than just a bodega cat—he was our neighborhood ambassador, our security guard, and everyone's best friend. On October 28, 2025, KitKat's life was tragically cut short when he was allegedly struck by a Waymo autonomous vehicle. The community is heartbroken. This token honors his memory and demands justice for all innocent lives.

Remember KitKat

KitKat Crypto is trending amid mixed sentiment, with some community members expressing frustration over price action and alleged bot manipulation. Others remain bullish, emphasizing the project's mission and potential, though they acknowledge challenges in boosting volume and holders. The community is also discussing news coverage and its limited impact on the coin's performance.

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Sagimet Biosciences Inc - Ordinary Shares - Series A

Sagimet Biosciences Inc

SGMT is trending as the community anticipates updates at an investor conference next week and discusses the potential of their acne treatment in China, with one partner planning to submit an NDA soon. Bullish investors are highlighting the low float and potential for a significant move, while others express concern about the lack of recent news and possible dilution. Community members are also debating the company's MASH program and potential partnerships.

Coya Therapeutics, Inc. is a clinical-stage biotechnology company which engages in developing proprietary medicinal products to modulate the function of regulatory T cells. The company was founded by Howard Berman in 2020 and is headquartered in Houston, TX.

Coya Therapeutics Inc

COYA is trending due to positive sentiment around its therapeutic approach for neurodegenerative diseases, particularly after study results showing anti-inflammatory effects in Alzheimer's patients. Community members are discussing potential partnerships and upcoming milestones, with some speculating on a possible acquisition by Dr. Reddy's. The stock's low float and recent analyst target price increases also contribute to the heightened interest.

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Bozeman, MT.

Snowflake Inc

Snowflake is experiencing heightened community interest, fueled by discussions around a potential 'volume-backed rally' and positive technical setups. Community members are actively evaluating call options and identifying key price levels, while analysts are weighing the company's AI strategy and partnerships against valuation concerns in the competitive data cloud sector. Overall sentiment suggests anticipation for continued momentum, with some eyeing potential new highs.

Sperax is redefining financial autonomy through programmable agents that manage capital, optimize yield, and protect against risk, all transparently on-chain. Founded in 2019, Sperax is backed by leading investors including Jump Trading, Polychain Capital, Amber Group. Sperax offers a new standard in automated, user-driven finance.  The SperaxOS ecosystem is powered by USDs and SPA on Arbitrum, BNB Chain, and other EVM networks. Anchored by two native assets: USDs, a gas-free, auto-yield stablecoin backed by on-chain collateral, and SPA, the governance and value-capture token. Sperax builds open-source tools that turn idle capital into self-optimizing portfolios.  SperaxOS is a cross-chain financial operating system where AI-driven smart agents automate everything from yield farming to payroll, and Demeter, a no-code platform for launching liquidity farms. USDs automatically rebases yield to holders, while SPA lets users register agents, earn protocol fees, and vote on upgrades. Battle-tested through multiple market cycles: Sperax offers individuals, DAOs, and fintechs a borderless toolkit for passive income, risk-managed investing, and fully automated treasury operations, all governed on-chain by its community.

Sperax

Sperax ($SPA) is trending as traders anticipate a potential breakout, fueled by discussions around its low market cap and upcoming developments like the SperaxOS launch. The community is closely watching for a move past key resistance levels, with some suggesting a significant rally is on the horizon. Bullish sentiment is building, with many highlighting its potential compared to other altcoins in the current market.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

CAPR is trending due to speculation surrounding the upcoming HOPE-3 trial data release for Duchenne Muscular Dystrophy, with community discussions focused on potential outcomes and impacts on the company's valuation. Concerns about a recent short report and its potential impact, along with varying opinions on the company's leadership and the therapy's efficacy, are fueling the conversation. Some traders are anticipating a short squeeze should the data prove positive, while others remain cautious, citing past failures and regulatory hurdles.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta (KTA) is trending due to community excitement around its potential as foundational infrastructure for TradFi, emphasized by its high throughput and compliance-aware design. Investors are actively discussing the token's value proposition in comparison to major platforms like Amazon, Google, and Microsoft, viewing KTA as a targeted bet on the future of financial plumbing. The community also highlights potential partnerships, particularly with Stripe, as a key catalyst.

Builders FirstSource, Inc. engages in the supply and manufacture of building materials, manufactured components, and construction services to professional homebuilders, sub-contractors, remodelers, and consumers. Its products include factory-built roof and floor trusses, wall panels and stairs, vinyl windows, custom millwork and trim, and engineered wood. The company was founded by Kevin P. O'Meara, Donald F. McAleenan and John D. Roach in March 1998 and is headquartered in Irving, TX.

Builders Firstsource Inc

Builders Firstsource is trending amidst discussions about housing market dynamics and potential interest rate cuts. The community is analyzing recent earnings, insider activity, and technical indicators to gauge future performance. Some anticipate a buyout, while others focus on the company's long-term growth potential within the construction sector.

Box, Inc. engages in the provision of an enterprise content platform that enables organizations to securely manage enterprise content while allowing easy, secure access and sharing of this content from anywhere, on any device. Its products include cloud content management, IT and admin controls, Box Governance, Box Zones, Box Relay, Box Shuttle, and Box KeySafe. The company was founded by Aaron Levie, Dylan Smith, Jeff Queisser, and Sam Ghods in March 2005 and is headquartered in Redwood City, CA.

Box Inc - Ordinary Shares - Class A

Box Inc

Box Inc is trending as options activity surges and analysts adjust price targets. Community members are weighing the company's potential amid discussions of AI integration and revenue growth. Some traders are closely watching key technical levels and anticipating a significant price move following earnings.

Direxion Shares ETF Trust - Direxion Daily Small Cap Bear 3X Shares

Direxion Daily Small Cap Bear 3X Shares

TZA is trending as traders discuss potential market reversals and the impact on small-cap stocks, given recent low volume rallies. Community members are actively trading TZA, with some citing technical indicators suggesting a buying opportunity while others remain cautious, waiting for a clearer market direction and considering it as a hedge. The discussion includes mentions of upcoming economic data and potential government actions that could influence market volatility and small-cap performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Coya Therapeutics, Inc. (NASDAQ:COYA) Given Consensus Rating of "Moderate Buy" by Brokerages

Coya Therapeutics, Inc. (NASDAQ:COYA - Get Free Report) has been assigned an average rating of "Moderate Buy" from the six analysts that are presently covering the stock, MarketBeat reports. One...

Coya Therapeutics (NASDAQ:COYA) Receives "Buy" Rating from Chardan Capital

Chardan Capital restated a "buy" rating and issued a $14.00 target price on shares of Coya Therapeutics in a report on Friday...

Coya Therapeutics (NASDAQ:COYA) Rating Increased to Hold at Wall Street Zen

Wall Street Zen raised Coya Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...

Coya Therapeutics (NASDAQ:COYA) Stock Price Expected to Rise, BTIG Research Analyst Says

BTIG Research increased their price objective on Coya Therapeutics from $15.00 to $16.00 and gave the company a "buy" rating in a research note on Thursday...

Coya Therapeutics (NASDAQ:COYA) Receives Buy Rating from D. Boral Capital

D. Boral Capital reissued a "buy" rating and set a $15.00 price target on shares of Coya Therapeutics in a research note on Wednesday...

Coya Therapeutics (NASDAQ:COYA) Releases Earnings Results, Misses Estimates By $0.12 EPS

Coya Therapeutics (NASDAQ:COYA - Get Free Report) announced its earnings results on Wednesday. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus...

Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update

Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with...

Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo

Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, today announced...

Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters Option to Purchase Additional Shares

Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock

$AMZN

$MSFT

$GOOGL

$ORCL

Which cloud infrastructure stock offers the best long-term opportunity right now?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.28	--	--	N/A
Q3 '25	-$0.23	-$0.13	44.24%	BEAT
Q2 '25	-$0.42	-$0.36	14.01%	BEAT
Q1 '25	-$0.19	-$0.44	-127.04%	MISSED
Q4 '24	-$0.28	-$0.18	34.64%	BEAT

COYA
Coya Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest COYA News

COYACoya Therapeutics Inc